Advancing optogenetic therapies for retinal diseases: a regulatory vision
Year: 2025
Type: article
Abstract: “We are at an exciting stage in our drug development program, and I am committed to advancing Nanoscope’s mission, driving regulatory success, and supporting our pipeline’s growth.” Jokūbas Leikauskas, Editor, Cell & Gene Therapy Insights, speaks to Ananta Ayyagari, Director of Regulatory and Intellectual Property, Nanoscope Therapeutics Inc. about the regulatory landscape of optogenetic therapies for retinal degenerative diseases, and clinical trial progress. They also discuss the evolving patent landscape for gene therapies, and the regulatory challenges in developing and commercializing such transformative treatments.
Source: Cell and Gene Therapy Insights
Author: Ananta Ayyagari
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
OpenAlex ID: W4417328765
FWCI:
Cites:
Cited by:
Related to: